Get notified when ZNTL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate and Substantial Dilution (new) — The offering price is substantially greater than net tangible book value per share, causing immediate and substantial dilution to new investors.
- No Market For Pre-funded Warrants (new) — The pre-funded warrants will not be listed on any exchange and no trading market is expected to develop, limiting liquidity for holders.
Zentalis Pharmaceuticals files preliminary prospectus for common stock and pre-funded warrant offering; terms not yet set
Filed August 13, 2026 · ~2 min read
Key Changes
-
high
Zentalis is offering common stock and pre-funded warrants, but the number of shares and pricing terms are left blank in this preliminary prospectus supplement.
The Offering verify on EDGAR → -
medium
The company's stock closed at $4.29 on August 12, 2026, providing a reference point for the offering price, which has not yet been determined.
The Offering verify on EDGAR → -
medium
Net proceeds will fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostic, pre-commercial activities, capex, working capital, and general corporate purposes.
Use of Proceeds verify on EDGAR →
4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade ZNTL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify